Press Release | JW Therapeutics

Press Release

JW Therapeutics' Relma-cel IIT Study in Systemic Sclerosis (SSc) Selected as Late-Breaking Abstract at the Systemic Sclerosis World Congress (SSWC)

05 March, 2026

JW Therapeutics Presents JWCAR201 IIT Study Data at the 67th American Society of Hematology Annual Meeting

08 December, 2025

JW Therapeutics' Carteyva® Successfully Included in the First Edition of the National Healthcare Security Administration's Commercial Health Insurance Innovative Drug Directory

07 December, 2025

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development

30 October, 2025

National Medical Products Administration has officially accepted the post-marketing supplemental application for Carteyva®, which uses an in-house produced lentiviral vector

09 October, 2025

JW Therapeutics Completes First Patient Infusion in Clinical Study of JWCAR239 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

26 September, 2025

JW Therapeutics Announces Approval of Carteyva® (Relmacabtagene Autoleucel Injection) for Marketing in Macao

04 June, 2025

NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA® AS SECOND-LINE TREATMENT IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

28 May, 2025

Next Generation MAGE-A4 TCR-T cell program in China

29 April, 2025

JW Therapeutics Announces sLVV License Agreement with Juno Therapeutics

23 April, 2025

Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

10 January, 2025

JW Therapeutics Won the “CNR” Corporate Social Responsibility 2024 ESG Era Pioneer Award

26 December, 2024

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

27 August, 2024

JW Therapeutics Appoints Min Liu as Chief Executive Officer

31 July, 2024

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

30 May, 2024

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

04 January, 2024

JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy

02 January, 2024

JW Therapeutics Presents Latest Clinical Response on Carteyva® (relmacabtagene autoleucel injection) in Adults with relapsed/refractory mantle cell lymphoma (r/r MCL) in China at the 65th ASH Annual Meeting

12 December, 2023

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

10 April, 2023

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

30 March, 2023

JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

08 March, 2023

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

28 February, 2023

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

12 December, 2022

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

09 November, 2022

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

27 October, 2022

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

10 October, 2022

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

04 July, 2022

JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting

05 June, 2022

JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting

09 May, 2022

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

25 April, 2022

JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

20 April, 2022

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

03 April, 2022

JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma

31 March, 2022

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

27 February, 2022

JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

10 January, 2022

JW Therapeutics Presents Primary Clinical Response on Carteyva® (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting

13 December, 2021

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

27 September, 2021

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

26 September, 2021

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

06 September, 2021

JW Therapeutics Announces 2021 Interim Results

27 August, 2021

JW Therapeutics Announces Strategic Partnership with MediTrust Health

20 August, 2021

JW Therapeutics Announces 2020 Annual Results

26 March, 2021

JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China

03 February, 2021

JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting

07 December, 2020

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX

03 November, 2020

JW Therapeutics and Lyell Immunopharma Announce Collaboration to Advance Solid Tumor Treatment in China

10 August, 2020

JW Acquires Syracuse Biopharma

20 July, 2020

JW Therapeutics Completes $ 100 Million Series B Financing

09 June, 2020

JW Therapeutics announced the grand opening of R&D center in Zhangjiang Science City of Pudong New Area, Shanghai

12 December, 2018

JW Therapeutics to Build Its First Commercial CAR-T Cell Manufacturing Plant in Suzhou, China

10 August, 2018

JW Therapeutics Closes $ 90 Million Series A Financing

08 March, 2018

JW Therapeutics Submitted data from the Phase I study of Relma-cel in Chinese adult patients with active systemic lupus erythematosus to China National Medical Products Administration

01 January, 0001

站点地图